logo

Pulse Biosciences, Inc. (Plse) (PLSE)



Trade PLSE now with
  Date
  Headline
10/6/2022 8:07:52 AM Pulse Biosciences Announces Positive Clinical Data On Nano-Pulse Stimulation Procedure For Low-Risk BCC Lesions
9/26/2022 8:10:25 AM Pulse Biosciences Announces FDA 510(k) Clearance For Sebaceous Hyperplasia
8/4/2022 8:12:39 AM Pulse Biosciences Gets FDA 510(k) Clearance Of Expanded Energy Settings For Use With CellFX System
2/8/2022 8:52:59 AM Pulse Biosciences Updates On Recent FDA 510(k) Submission; Stock Down
1/11/2022 7:06:35 AM Pulse Biosciences Expects Full Year 2021 Revenue To Be $1.3 Mln To $1.4 Mln
11/15/2021 4:12:32 PM Pulse Biosciences Q3 Loss/share $0.48 Vs. Loss $0.51 Year Ago
10/5/2021 8:08:03 AM Pulse Biosciences Appoints Laureen DeBuono To Board
8/19/2021 4:10:03 PM Pulse Biosciences Appoints Mitchell Levinson As Chief Strategy Officer
7/1/2021 8:05:01 AM Pulse Biosciences Announces $50 Mln Private Placement
6/30/2021 10:24:46 AM Pulse Biosciences Says First Patient In Canada Treated With CellFX Procedure
6/9/2021 8:14:26 AM Pulse Biosciences Announces Health Canada Approval For CellFX System For Use In Dermatological Procedures
5/13/2021 9:53:18 AM Pulse Biosciences Presents Study Results Of Nano-Pulse Stimulation Technology To Clear Benign Lesions
2/19/2021 8:12:10 AM Pulse Biosciences Says First CellFX Procedures In European Union Were Successfully Completed
2/3/2021 9:04:57 AM Pulse Biosciences Receives FDA Clearance Of CellFX System For Dermatologic Procedures
1/25/2021 8:13:47 AM Pulse Biosciences Announces Conformit Europene Mark Approval For The CellFX System